By Fineline Cube 
Roche Holding AG (SWX: ROP; OTCMKTS: RHHBY) announced that China’s National Medical Products Administration (NMPA) has granted formal approval for the single-dose pre-filled syringe formulation of Vabysmo (faricimab) to treat neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO).
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | NMPA (China) |
| Approval Type | Full marketing authorization |
| Product | Vabysmo (faricimab) pre-filled syringe (PFS) |
| Indications | nAMD, DME, and RVO-related macular edema |
| Approval Date | 31 Jul 2026 |
| Next Steps | Commercial launch expected Q3 2026 |
Drug Profile & Mechanism of Action
- Molecule: Faricimab – the world’s first bispecific antibody engineered specifically for intraocular injection
- Dual Targets: Simultaneously inhibits vascular endothelial growth factor A (VEGF-A) and angiopoietin-2 (Ang-2)
- Innovation: Addresses both abnormal blood vessel growth and vascular destabilization, reducing leakage, inflammation, and fibrosis more comprehensively than single-pathway inhibitors
- Clinical Advantage: Enables extended treatment intervals while maintaining visual acuity, potentially reducing treatment burden for patients
Clinical Evidence – Global Phase III Program
| Trial | Indication | Key Outcome |
|---|---|---|
| TENAYA/LUCERNE | nAMD | 44–45% of patients maintained vision with dosing every 16 weeks vs. every 8 weeks for aflibercept |
| YOSEMITE/RHINE | DME | Superior reduction in central subfield thickness vs. aflibercept at week 52 |
| BALATON/COMINO | RVO | Met primary endpoint of non-inferiority in best-corrected visual acuity at week 24 |
The global development program enrolled over 3,600 patients across multiple continents, establishing Vabysmo’s safety profile and efficacy across diverse retinal disease populations.
Market Impact & Strategic Outlook
- China Ophthalmology Market: Valued at $1.2 billion in 2025, projected to grow at 15% CAGR through 2030, driven by aging demographics and rising diabetes prevalence
- Competitive Positioning: Vabysmo’s dual-pathway approach differentiates it from established anti-VEGF monotherapies (e.g., Lucentis, Eylea) by potentially offering longer durability
- Revenue Potential: With CHF 480 million ($530 million) in global sales during H1 2026, China represents a significant growth vector for Roche’s ophthalmology franchise
- Commercial Strategy: Roche plans to leverage its established hospital and specialty pharmacy network, with pricing and reimbursement negotiations underway for provincial formulary inclusion by early 2027
Forward-Looking Statements
This brief contains forward-looking statements regarding regulatory approvals, commercial timelines, and market expectations for Vabysmo. Actual results may differ due to risks including market adoption rates, competitive dynamics, and healthcare policy changes in China.-Fineline Info & Tech